Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cryoelectron Microscopy | 8 | 2022 | 91 | 1.850 |
Why?
|
Pancreatic Neoplasms | 9 | 2021 | 645 | 1.470 |
Why?
|
Membrane Proteins | 4 | 2023 | 1196 | 1.150 |
Why?
|
Symporters | 2 | 2024 | 107 | 1.060 |
Why?
|
Immunoglobulin Fab Fragments | 3 | 2022 | 81 | 1.030 |
Why?
|
Models, Molecular | 9 | 2021 | 1286 | 1.000 |
Why?
|
Antibodies | 3 | 2022 | 350 | 0.970 |
Why?
|
Bile Acids and Salts | 2 | 2024 | 61 | 0.900 |
Why?
|
Chemoradiotherapy | 5 | 2019 | 301 | 0.850 |
Why?
|
Single-Domain Antibodies | 1 | 2021 | 4 | 0.840 |
Why?
|
Maltose-Binding Proteins | 2 | 2018 | 31 | 0.770 |
Why?
|
Cell Surface Display Techniques | 3 | 2020 | 16 | 0.760 |
Why?
|
Induction Chemotherapy | 2 | 2019 | 147 | 0.660 |
Why?
|
Escherichia coli K12 | 1 | 2018 | 4 | 0.640 |
Why?
|
Maltose | 1 | 2018 | 33 | 0.640 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 2436 | 0.630 |
Why?
|
Antibodies, Blocking | 1 | 2018 | 21 | 0.630 |
Why?
|
Molecular Probes | 1 | 2018 | 35 | 0.630 |
Why?
|
Protein Conformation | 6 | 2022 | 881 | 0.610 |
Why?
|
Escherichia coli Proteins | 1 | 2018 | 179 | 0.570 |
Why?
|
Neoplasms, Second Primary | 1 | 2019 | 252 | 0.560 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2015 | 20 | 0.540 |
Why?
|
Calmodulin | 1 | 2015 | 50 | 0.530 |
Why?
|
Adenocarcinoma | 3 | 2019 | 1169 | 0.510 |
Why?
|
Deoxycytidine | 4 | 2017 | 237 | 0.500 |
Why?
|
Nelfinavir | 3 | 2019 | 5 | 0.460 |
Why?
|
Protein Binding | 5 | 2021 | 1456 | 0.450 |
Why?
|
Fluorouracil | 2 | 2017 | 556 | 0.430 |
Why?
|
Peptide Library | 4 | 2022 | 84 | 0.420 |
Why?
|
Crystallography, X-Ray | 4 | 2020 | 485 | 0.420 |
Why?
|
Staphylococcus aureus | 2 | 2015 | 263 | 0.390 |
Why?
|
G-Protein-Coupled Receptor Kinase 1 | 2 | 2021 | 4 | 0.390 |
Why?
|
Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 27 | 0.380 |
Why?
|
Rhodopsin | 2 | 2021 | 19 | 0.370 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2009 | 46 | 0.350 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 73 | 0.350 |
Why?
|
Capecitabine | 4 | 2019 | 96 | 0.350 |
Why?
|
GTP-Binding Protein alpha Subunits, Gi-Go | 2 | 2019 | 15 | 0.350 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2021 | 108 | 0.320 |
Why?
|
Polymers | 2 | 2020 | 202 | 0.300 |
Why?
|
Biotinylation | 2 | 2018 | 41 | 0.290 |
Why?
|
Thermodynamics | 5 | 2019 | 309 | 0.290 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2009 | 276 | 0.290 |
Why?
|
DNA Damage | 2 | 2019 | 366 | 0.290 |
Why?
|
Antineoplastic Agents | 2 | 2019 | 2357 | 0.280 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2016 | 94 | 0.260 |
Why?
|
Biological Transport | 2 | 2023 | 396 | 0.260 |
Why?
|
Recombinant Proteins | 3 | 2019 | 1014 | 0.250 |
Why?
|
Humans | 30 | 2024 | 86601 | 0.250 |
Why?
|
Lipopeptides | 1 | 2024 | 16 | 0.240 |
Why?
|
Solute Carrier Organic Anion Transporter Family Member 1B3 | 1 | 2023 | 4 | 0.240 |
Why?
|
Amino Acid Sequence | 4 | 2021 | 2062 | 0.240 |
Why?
|
Hepatitis B | 1 | 2024 | 74 | 0.230 |
Why?
|
Esophageal Neoplasms | 2 | 2016 | 321 | 0.230 |
Why?
|
Mannosyltransferases | 1 | 2023 | 6 | 0.230 |
Why?
|
Wnt Signaling Pathway | 2 | 2021 | 91 | 0.220 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 2 | 2019 | 19 | 0.220 |
Why?
|
Nuclear Pore | 1 | 2022 | 11 | 0.220 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2022 | 13 | 0.220 |
Why?
|
Tryptophan | 1 | 2023 | 90 | 0.220 |
Why?
|
RNA Transport | 1 | 2022 | 11 | 0.220 |
Why?
|
Kinetics | 4 | 2019 | 1513 | 0.220 |
Why?
|
Aurora Kinase B | 1 | 2022 | 14 | 0.220 |
Why?
|
Camelids, New World | 1 | 2021 | 3 | 0.210 |
Why?
|
Camelus | 1 | 2021 | 5 | 0.210 |
Why?
|
Sequence Analysis, Protein | 1 | 2021 | 28 | 0.210 |
Why?
|
Combined Modality Therapy | 4 | 2019 | 1685 | 0.210 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2022 | 58 | 0.210 |
Why?
|
Fungal Proteins | 1 | 2022 | 141 | 0.200 |
Why?
|
Multiprotein Complexes | 1 | 2022 | 95 | 0.200 |
Why?
|
GATA6 Transcription Factor | 1 | 2021 | 13 | 0.200 |
Why?
|
Lipids | 1 | 2023 | 269 | 0.200 |
Why?
|
Cytoplasm | 1 | 2022 | 281 | 0.200 |
Why?
|
Disease-Free Survival | 5 | 2017 | 1204 | 0.200 |
Why?
|
Mutation | 4 | 2019 | 3967 | 0.200 |
Why?
|
Microscopy, Electron | 1 | 2021 | 503 | 0.200 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2021 | 64 | 0.200 |
Why?
|
Sodium | 1 | 2022 | 341 | 0.200 |
Why?
|
Dioxygenases | 1 | 2021 | 74 | 0.190 |
Why?
|
Sequence Alignment | 1 | 2021 | 351 | 0.190 |
Why?
|
Protein Engineering | 2 | 2021 | 140 | 0.190 |
Why?
|
Frizzled Receptors | 1 | 2020 | 15 | 0.190 |
Why?
|
Enzyme Inhibitors | 2 | 2017 | 639 | 0.190 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2022 | 164 | 0.190 |
Why?
|
Signal Transduction | 4 | 2021 | 3241 | 0.190 |
Why?
|
Propylamines | 1 | 2020 | 9 | 0.190 |
Why?
|
Publications | 1 | 2020 | 26 | 0.190 |
Why?
|
Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 3 | 0.180 |
Why?
|
5-Methylcytosine | 1 | 2021 | 112 | 0.180 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 388 | 0.170 |
Why?
|
Ligands | 2 | 2018 | 433 | 0.170 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2022 | 382 | 0.160 |
Why?
|
Apoproteins | 1 | 2018 | 22 | 0.160 |
Why?
|
Radiation Dosage | 1 | 2019 | 227 | 0.160 |
Why?
|
Antibody Affinity | 1 | 2018 | 38 | 0.160 |
Why?
|
Metformin | 2 | 2021 | 128 | 0.160 |
Why?
|
Substrate Specificity | 3 | 2018 | 347 | 0.160 |
Why?
|
Protein Stability | 1 | 2018 | 99 | 0.160 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 429 | 0.160 |
Why?
|
Catalysis | 3 | 2017 | 203 | 0.150 |
Why?
|
Biomarkers, Pharmacological | 1 | 2017 | 22 | 0.150 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2017 | 138 | 0.150 |
Why?
|
Survival Analysis | 2 | 2019 | 1538 | 0.150 |
Why?
|
Galactose | 1 | 2016 | 32 | 0.150 |
Why?
|
Liver | 1 | 2022 | 1229 | 0.150 |
Why?
|
Duodenum | 1 | 2017 | 100 | 0.150 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 479 | 0.150 |
Why?
|
Cell Membrane | 1 | 2020 | 666 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2017 | 51 | 0.150 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 339 | 0.140 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 199 | 0.140 |
Why?
|
Lectins | 1 | 2016 | 84 | 0.140 |
Why?
|
Isoxazoles | 1 | 2016 | 77 | 0.140 |
Why?
|
Animals | 7 | 2021 | 26581 | 0.140 |
Why?
|
DNA Methylation | 1 | 2021 | 628 | 0.140 |
Why?
|
Transcription, Genetic | 1 | 2021 | 1135 | 0.140 |
Why?
|
HIV Protease Inhibitors | 1 | 2016 | 21 | 0.140 |
Why?
|
Binding Sites | 4 | 2021 | 1098 | 0.140 |
Why?
|
RNA, Messenger | 1 | 2022 | 1981 | 0.140 |
Why?
|
Pyrazines | 1 | 2016 | 92 | 0.140 |
Why?
|
Radiation Injuries | 1 | 2017 | 155 | 0.140 |
Why?
|
Recombinant Fusion Proteins | 1 | 2018 | 557 | 0.140 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 392 | 0.140 |
Why?
|
ras GTPase-Activating Proteins | 1 | 2015 | 10 | 0.140 |
Why?
|
Aminopeptidases | 1 | 2015 | 17 | 0.130 |
Why?
|
Protein Methyltransferases | 1 | 2015 | 14 | 0.130 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 49 | 0.130 |
Why?
|
Protein Processing, Post-Translational | 1 | 2018 | 371 | 0.130 |
Why?
|
Glycine | 1 | 2015 | 90 | 0.130 |
Why?
|
Histones | 1 | 2017 | 311 | 0.130 |
Why?
|
Phosphoglycerate Mutase | 1 | 2015 | 4 | 0.130 |
Why?
|
Treatment Outcome | 3 | 2019 | 7988 | 0.130 |
Why?
|
Receptors, Prolactin | 1 | 2015 | 10 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
Single-Chain Antibodies | 1 | 2015 | 17 | 0.130 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 1208 | 0.130 |
Why?
|
Rectal Neoplasms | 1 | 2016 | 116 | 0.130 |
Why?
|
Leptin | 1 | 2015 | 105 | 0.130 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2015 | 154 | 0.120 |
Why?
|
Epitopes | 1 | 2015 | 255 | 0.120 |
Why?
|
Pandemics | 1 | 2020 | 740 | 0.120 |
Why?
|
Catalytic Domain | 2 | 2015 | 156 | 0.120 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2015 | 302 | 0.120 |
Why?
|
HEK293 Cells | 1 | 2015 | 615 | 0.110 |
Why?
|
Mice | 5 | 2021 | 11352 | 0.110 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 179 | 0.110 |
Why?
|
Health Status | 1 | 2015 | 360 | 0.110 |
Why?
|
Biomarkers, Tumor | 1 | 2021 | 1464 | 0.110 |
Why?
|
Androstadienes | 1 | 2012 | 72 | 0.110 |
Why?
|
Proteins | 1 | 2018 | 777 | 0.110 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 329 | 0.110 |
Why?
|
Aged | 4 | 2019 | 18402 | 0.110 |
Why?
|
Prednisone | 1 | 2012 | 258 | 0.110 |
Why?
|
Hypoglycemic Agents | 1 | 2015 | 378 | 0.100 |
Why?
|
Cell Line, Tumor | 4 | 2021 | 2426 | 0.100 |
Why?
|
Middle Aged | 5 | 2019 | 25017 | 0.100 |
Why?
|
Aged, 80 and over | 2 | 2019 | 6501 | 0.100 |
Why?
|
Blood Glucose | 1 | 2015 | 873 | 0.100 |
Why?
|
Antibodies, Monoclonal | 1 | 2017 | 1376 | 0.100 |
Why?
|
Male | 7 | 2019 | 40956 | 0.090 |
Why?
|
Cell Line | 1 | 2015 | 2468 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 860 | 0.090 |
Why?
|
Biocatalysis | 1 | 2010 | 51 | 0.090 |
Why?
|
Butyric Acid | 1 | 2009 | 11 | 0.090 |
Why?
|
Maleimides | 1 | 2009 | 29 | 0.090 |
Why?
|
Insulin | 1 | 2015 | 1160 | 0.090 |
Why?
|
Phosphorylation | 2 | 2022 | 1106 | 0.090 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2009 | 279 | 0.080 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 1034 | 0.080 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2009 | 416 | 0.080 |
Why?
|
Adult | 3 | 2019 | 25640 | 0.080 |
Why?
|
Female | 6 | 2019 | 44507 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 458 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2016 | 2600 | 0.080 |
Why?
|
Quality of Life | 1 | 2015 | 1583 | 0.080 |
Why?
|
Young Adult | 1 | 2019 | 5974 | 0.070 |
Why?
|
Protein Structure, Tertiary | 2 | 2021 | 736 | 0.070 |
Why?
|
Adolescent | 1 | 2019 | 8979 | 0.070 |
Why?
|
Neoplasm Staging | 3 | 2016 | 1937 | 0.070 |
Why?
|
United Kingdom | 2 | 2015 | 164 | 0.060 |
Why?
|
Statistics, Nonparametric | 2 | 2015 | 307 | 0.060 |
Why?
|
Radiotherapy Dosage | 2 | 2017 | 468 | 0.060 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 3030 | 0.060 |
Why?
|
Hepatitis Delta Virus | 1 | 2024 | 9 | 0.060 |
Why?
|
Hepatitis B virus | 1 | 2024 | 43 | 0.060 |
Why?
|
Virus Internalization | 1 | 2024 | 39 | 0.060 |
Why?
|
Receptors, Virus | 1 | 2024 | 74 | 0.060 |
Why?
|
Hepatocytes | 1 | 2024 | 127 | 0.060 |
Why?
|
Anions | 1 | 2023 | 31 | 0.060 |
Why?
|
Chaetomium | 1 | 2022 | 3 | 0.050 |
Why?
|
Glycosylation | 1 | 2023 | 129 | 0.050 |
Why?
|
Membrane Transport Proteins | 1 | 2023 | 166 | 0.050 |
Why?
|
Platinum | 1 | 2022 | 63 | 0.050 |
Why?
|
Phthalazines | 1 | 2022 | 39 | 0.050 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 72 | 0.050 |
Why?
|
Spindle Apparatus | 1 | 2022 | 65 | 0.050 |
Why?
|
Molecular Chaperones | 1 | 2022 | 111 | 0.050 |
Why?
|
Disease Models, Animal | 2 | 2019 | 2232 | 0.050 |
Why?
|
Adenosine Monophosphate | 1 | 2021 | 27 | 0.050 |
Why?
|
Mitosis | 1 | 2022 | 153 | 0.050 |
Why?
|
Smad4 Protein | 1 | 2021 | 23 | 0.050 |
Why?
|
Ascorbic Acid | 1 | 2021 | 37 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2012 | 1720 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 2015 | 2887 | 0.050 |
Why?
|
Protein Domains | 1 | 2021 | 128 | 0.050 |
Why?
|
Cattle | 1 | 2021 | 376 | 0.050 |
Why?
|
Cytoskeleton | 1 | 2022 | 193 | 0.050 |
Why?
|
Epigenomics | 1 | 2021 | 100 | 0.050 |
Why?
|
Adenosine Triphosphate | 1 | 2021 | 314 | 0.050 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 1056 | 0.050 |
Why?
|
Antiviral Agents | 1 | 2024 | 510 | 0.050 |
Why?
|
Protein Conformation, beta-Strand | 1 | 2019 | 15 | 0.050 |
Why?
|
Protein Conformation, alpha-Helical | 1 | 2019 | 16 | 0.050 |
Why?
|
Antibody Specificity | 1 | 2019 | 129 | 0.040 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2019 | 86 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 378 | 0.040 |
Why?
|
Peptides | 1 | 2023 | 639 | 0.040 |
Why?
|
Mice, Nude | 1 | 2021 | 790 | 0.040 |
Why?
|
Arrestin | 1 | 2018 | 5 | 0.040 |
Why?
|
Cloning, Molecular | 1 | 2019 | 646 | 0.040 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2018 | 36 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2019 | 357 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2019 | 439 | 0.040 |
Why?
|
Zirconium | 1 | 2017 | 2 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2015 | 3636 | 0.040 |
Why?
|
Radioisotopes | 1 | 2017 | 45 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2021 | 1540 | 0.040 |
Why?
|
Gels | 1 | 2016 | 48 | 0.040 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2017 | 86 | 0.040 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 52 | 0.040 |
Why?
|
Transcriptome | 1 | 2021 | 580 | 0.040 |
Why?
|
Escherichia coli | 1 | 2019 | 597 | 0.040 |
Why?
|
Molecular Structure | 1 | 2016 | 287 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 1197 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2017 | 692 | 0.030 |
Why?
|
Switzerland | 1 | 2015 | 17 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 1384 | 0.030 |
Why?
|
Gene Expression | 1 | 2019 | 1284 | 0.030 |
Why?
|
Prolactin | 1 | 2015 | 88 | 0.030 |
Why?
|
Manganese | 1 | 2015 | 53 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2015 | 54 | 0.030 |
Why?
|
Motion | 1 | 2015 | 85 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2021 | 1458 | 0.030 |
Why?
|
X-Ray Diffraction | 1 | 2015 | 124 | 0.030 |
Why?
|
North America | 1 | 2015 | 180 | 0.030 |
Why?
|
Fatigue | 1 | 2015 | 174 | 0.030 |
Why?
|
Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2015 | 190 | 0.030 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 146 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 916 | 0.030 |
Why?
|
Multimodal Imaging | 1 | 2014 | 110 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2014 | 176 | 0.030 |
Why?
|
Feeding and Eating Disorders | 1 | 2015 | 173 | 0.030 |
Why?
|
Abiraterone Acetate | 1 | 2012 | 11 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 176 | 0.030 |
Why?
|
Medical Oncology | 1 | 2016 | 359 | 0.030 |
Why?
|
Societies, Medical | 1 | 2016 | 572 | 0.030 |
Why?
|
Cisplatin | 1 | 2014 | 612 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2012 | 150 | 0.030 |
Why?
|
Body Mass Index | 1 | 2015 | 770 | 0.030 |
Why?
|
Research Design | 1 | 2015 | 594 | 0.020 |
Why?
|
Cohort Studies | 1 | 2017 | 2767 | 0.020 |
Why?
|
Computer Simulation | 1 | 2015 | 1078 | 0.020 |
Why?
|
Biomarkers | 1 | 2016 | 1718 | 0.020 |
Why?
|
Prospective Studies | 1 | 2017 | 4210 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2012 | 1823 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2021 | 8475 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2015 | 2501 | 0.020 |
Why?
|
Prognosis | 1 | 2014 | 3674 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 3352 | 0.010 |
Why?
|
United States | 1 | 2016 | 6665 | 0.010 |
Why?
|